ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals Inc (ADMS)

8.22
0.00
( 0.00% )
Updated: 19:00:00

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
8.22
Bid
9.33
Ask
8.30
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
8.22
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

ADMS Latest News

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

ROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas...

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust...

Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one...

Adamas Announces New Employment Inducement Grants

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted eight new employees restricted stock units to acquire...

Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today...

Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society’s (MDS) Congress

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today...

Adamas Announces New Employment Inducement Grants

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven new employees restricted stock units to acquire...

Adamas to Present at Upcoming September Investor Conferences

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PRFXPainReform Ltd
$ 1.2395
(131.68%)
175.86M
SMCXDefiance Daily Target 2X Long SMCI ETF
$ 41.87
(64.07%)
3.6M
NCNCnoco noco Inc
$ 0.159
(63.92%)
732.27M
SYRSSyros Pharmaceuticals Inc
$ 0.3169
(59.41%)
320.71M
ACRSAclaris Therapeutics Inc
$ 4.73
(50.64%)
48.47M
SLNSilence Therapeutics PLC
$ 7.165
(-34.98%)
2.92M
DFLIDragonfly Energy Holdings Corporation
$ 0.3383
(-32.60%)
2.52M
AKTXAkari Therapeutics PLC
$ 1.55
(-32.31%)
259.01k
DMNDamon Inc
$ 1.6439
(-31.79%)
712.96k
QMMMQMMM Holdings Limited
$ 1.2695
(-26.62%)
4.21M
NCNCnoco noco Inc
$ 0.1592
(64.12%)
732.27M
SYRSSyros Pharmaceuticals Inc
$ 0.3154
(58.65%)
320.78M
WBUYWeBuy Global Ltd
$ 0.1901
(19.48%)
247.79M
SMCISuper Micro Computer Inc
$ 28.4001
(31.85%)
194.51M
PRFXPainReform Ltd
$ 1.235
(130.84%)
175.87M

ADMS Discussion

View Posts
conix conix 3 years ago
ADMS Chart


πŸ‘οΈ0
wesley_ wesley_ 4 years ago
$6.10 nice
πŸ‘οΈ0
slow_feet slow_feet 4 years ago
Perhaps the "analysts" and their friends have loaded up now. I'm expecting them to issue their new expert estimates soon:

https://www.marketwatch.com/investing/stock/adms/analystestimates?mod=mw_quote_tab
πŸ‘οΈ0
mm107 mm107 4 years ago
i got caught up in those Halts. Chased only to see it get sold down.

such good news, doesnt really make sense
πŸ‘οΈ0
peterus peterus 4 years ago
approval and only %30 up
with low ss ?
πŸ‘οΈ0
slow_feet slow_feet 4 years ago
I bid for Feb and Mar 7.5 calls for 3 straight weeks in mid-January since I wanted as little time-value as possible. My average % gain is ~4300%. I closed ~19% of my calls last Friday to get my initial outlay back, since the news could have been neutral/bad, and released pre/post market.
πŸ‘οΈ0
peterus peterus 4 years ago
whats your pt here ?
πŸ‘οΈ0
slow_feet slow_feet 4 years ago
πŸ‘οΈ0
slow_feet slow_feet 4 years ago
Adamas Announces FDA Approval for Second Indication for GOCOVRI(R)

πŸ‘οΈ0
slow_feet slow_feet 4 years ago
Trading Halt

02/01/2021 13:00:14 ADMS Adamas Pharmaceuticals, Inc Cm NASDAQ T1

T1 Halt - News Pending
Trading is halted pending the release of material news.
πŸ‘οΈ0
slow_feet slow_feet 4 years ago
8-K: 2/1/21

Item 1.01 Entry Into a Material Definitive Agreement.

As previously disclosed, Adamas Pharma, LLC, a wholly-owned subsidiary of Adamas Pharmaceuticals, Inc. (the β€œCompany”) is involved in a lawsuit against Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA), Inc. (collectively β€œZydus”) in the United States District Court for the District of New Jersey alleging infringement of the Company’s patents by Zydus. On January 30, 2021, the Company entered into a definitive agreement (the β€œDefinitive Agreement”) with Zydus pursuant to which the parties agreed to end the lawsuit and dismiss it without prejudice. Pursuant to the Definitive Agreement, the Company grants a license to make, use, sell, offer to sell and import a generic version of GOCOVRI® (amantadine) extended release capsules, effective as of March 4, 2030, or earlier in certain circumstances typical for such agreements. In addition, the Definitive Agreement contains provisions that may accelerate the license date, including if unit sales of GOCOVRI in the 12-month period ending July 31, 2025 or any subsequent 12-month period decline by a specified percentage below GOCOVRI unit sales in the year ended December 31, 2019.

The Definitive Agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice. The Company expects to file the Definitive Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending March 31, 2021.

Zydus Pharmaceuticals
πŸ‘οΈ0
slow_feet slow_feet 4 years ago
Letting go of a small % of my ADMS calls, into the close, to cover initial outlay.

Calls are popping in the microwave...
πŸ‘οΈ0
slow_feet slow_feet 4 years ago
MM's straightening the books in AH:

πŸ‘οΈ0
slow_feet slow_feet 4 years ago
ADMS: ~71% of ~29M OS held by insiders/funds. This implies only ~8M of the ~19M float is tradable, provided the funds hang on.
πŸ‘οΈ0
slow_feet slow_feet 4 years ago
Looks like someone has noticed ADMS. Now just need pps over $7.50 for Feb. Calls...
πŸ‘οΈ0
slow_feet slow_feet 4 years ago
(i) 2021-02-01
ADMS GOCOVRI (ADS-5102)
FDA Approval announced August 24, 2017. PDUFA date February 1, 2021 for sNDA to include treatment of OFF episodes in PD patients receiving levodopa.

(ii) revenue update
πŸ‘οΈ0
TFMG TFMG 4 years ago



$ADMS | #AdamasPharmaceuticals Upside Targets




Adamas Pharmaceuticals , Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.




πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $ADMS Video Chart 08-07-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Tanis2476 Tanis2476 5 years ago
Hey, remember when this was about to launch and the VP of Market Access, M. Masterson, was considered to be β€œthe most innovative person in Market Access?” LOLOLOLOLOL
πŸ‘οΈ0
Tanis2476 Tanis2476 5 years ago
Wow, nice swing and miss.
πŸ‘οΈ0
dinogreeves dinogreeves 5 years ago
Took a small position for 1000 shares on this, will likely hit $10 tomorrow plenty of cash on hand and news after hours.
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ADMS Video Chart 01-08-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ADMS Video Chart 12-18-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ADMS Video Chart 12-17-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ADMS Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
Tanis2476 Tanis2476 5 years ago
LOLOLOLOL!!!

At $130k a year, this extended release of an ages old drug prices itself out of any success.

Who the hell came up with the price?!? Hopefully the we’re terminated.
πŸ‘οΈ0
ADVFN_bioking ADVFN_bioking 5 years ago
strong buy
πŸ‘οΈ0
ADVFN_bioking ADVFN_bioking 5 years ago
load up before monster news hit the wire
πŸ‘οΈ0
ADVFN_bioking ADVFN_bioking 5 years ago
phase 3 results imminent
πŸ‘οΈ0
ADVFN_bioking ADVFN_bioking 5 years ago
trading massive under cash
πŸ‘οΈ0
ADVFN_bioking ADVFN_bioking 5 years ago
news coming
πŸ‘οΈ0
ADVFN_bioking ADVFN_bioking 5 years ago
good stock
πŸ‘οΈ0
Tanis2476 Tanis2476 5 years ago
This company continues to disappoint.
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ADMS Video Chart 10-04-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ADMS Video Chart 09-30-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ADMS Video Chart 09-20-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
whytestocks whytestocks 5 years ago
News: $ADMS ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, May 31, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ: ADMS ) f...

Find out more https://marketwirenews.com/news-releases/ongoing-investigation-alert-the-schall-law-firm-announces-it-is-investigating-claims-against-adamas-pharmaceuticals-inc-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-8278320.html
πŸ‘οΈ0
Tanis2476 Tanis2476 6 years ago
This is a garbage company with garbage leadership and a garbage product. People are resigning daily. Failed experiment. Look for $5 soon. It’s been a great Puts play.
πŸ‘οΈ0
0210 0210 6 years ago
very interesting. fundamentals + technicals. sitting on starter today.
πŸ‘οΈ0
CK56 CK56 6 years ago
Is anyone here??? Looks like a sign of life today, in AM anyway. When it moves it moves quickly due to the heavy ownership of tutes thereby little float available. We just need a couple of big boys to come in here. SP can easily go to $17 to 18 range where it should be right now. it has stepped down way too much. turn around seems to have begun.
πŸ‘οΈ0
Staypositive1 Staypositive1 7 years ago
Toying with a run into the close.
πŸ‘οΈ0
Staypositive1 Staypositive1 7 years ago
Getting ready for a run here.
πŸ‘οΈ0
RainyDayWriter RainyDayWriter 7 years ago
How may this affect ADMS?
https://finance.yahoo.com/news/acorda-files-parkinson-apos-drug-140002308.html
πŸ‘οΈ0
RainyDayWriter RainyDayWriter 7 years ago
Benefits of Gocovri in Parkinson's patients:
http://crweworld.com/article/news-provided-by-globenewswire/252730/adamas-announces-publication-of-data-supporting-the-benefits-of-gocovri-in-parkinsons-disease-patients-with-dyskinesia
πŸ‘οΈ0
Staypositive1 Staypositive1 7 years ago
Looks like a long waiting game.
πŸ‘οΈ0
Staypositive1 Staypositive1 7 years ago
How much do u like HGMT. Hearing calls for 15.
πŸ‘οΈ0
Dragonfly79 Dragonfly79 7 years ago
Hells yea
πŸ‘οΈ0
Staypositive1 Staypositive1 7 years ago
Looking good here compared to the rest of the market.
πŸ‘οΈ0
Staypositive1 Staypositive1 7 years ago
Very quickly.
πŸ‘οΈ0
Dragonfly79 Dragonfly79 7 years ago
I’m thinking soon. They just raised 85 million in a day at 41.50
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock